ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update

ImageneBio, Inc. (NASDAQ:IMA) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 104,900 shares, a growth of 180.5% from the September 30th total of 37,400 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average daily volume of 54,800 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 54,800 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.2% of the company’s stock are short sold.

Analyst Ratings Changes

A number of brokerages recently weighed in on IMA. Weiss Ratings began coverage on ImageneBio in a research note on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Wall Street Zen raised ImageneBio to a “hold” rating in a research report on Friday, September 26th. Leerink Partners started coverage on ImageneBio in a research report on Friday, October 24th. They set an “outperform” rating and a $30.00 target price on the stock. Zacks Research lowered ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Leerink Partnrs raised ImageneBio to a “strong-buy” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.67.

ImageneBio Stock Performance

Shares of IMA stock opened at $8.71 on Friday. The stock’s 50-day simple moving average is $9.09 and its 200-day simple moving average is $13.05. The firm has a market capitalization of $34.93 million, a PE ratio of -1.13 and a beta of 0.41. ImageneBio has a fifty-two week low of $7.24 and a fifty-two week high of $23.28.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IMA. XTX Topco Ltd boosted its stake in shares of ImageneBio by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after buying an additional 43,924 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of ImageneBio by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after buying an additional 29,369 shares during the last quarter. Aldebaran Capital LLC purchased a new stake in shares of ImageneBio in the first quarter worth about $317,000. Finally, BML Capital Management LLC boosted its stake in shares of ImageneBio by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock worth $4,750,000 after buying an additional 124,937 shares during the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.